Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.61B |
| 2 |
Microsoft
MSFT
|
+$1.17B |
| 3 |
Broadcom
AVGO
|
+$366M |
| 4 |
Merck
MRK
|
+$343M |
| 5 |
Meta Platforms (Facebook)
META
|
+$260M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$609M |
| 2 |
CMA
Comerica
CMA
|
+$512M |
| 3 |
CADE
Cadence Bank
CADE
|
+$422M |
| 4 |
Johnson & Johnson
JNJ
|
+$331M |
| 5 |
Western Digital
WDC
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.81% |
| 2 | Financials | 17.07% |
| 3 | Industrials | 12.54% |
| 4 | Consumer Discretionary | 10.14% |
| 5 | Healthcare | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
Pulmonx
LUNG
$49.4M
| $183K | ﹤0.01% |
141,920
-26,280
| -16% | -$43.4K |
|
3077
Research Solutions
RSSS
$73.6M
| $176K | ﹤0.01% |
77,962
+933
| +1% | +$2.38K |
|
3078
Gyre Therapeutics
GYRE
$662M
| $176K | ﹤0.01% |
25,268
+14,365
| +132% | +$112K |
|
|
SNBR
3079
DELISTED
Sleep Number
SNBR
| $174K | ﹤0.01% |
96,888
-138,486
| -59% | -$1.04M |
|
3080
ReposiTrak
TRAK
$148M
| $174K | ﹤0.01% |
22,869
-3,656
| -14% | -$35.1K |
|
3081
Franklin Wireless
FKWL
$27.6M
| $174K | ﹤0.01% |
45,553
+2
| +0% | +$8 |
|
3082
Bridger Aerospace
BAER
$107M
| $169K | ﹤0.01% |
+85,188
| New | +$208K |
|
3083
Cosan
CSAN
$2.96B
| $167K | ﹤0.01% |
40,418
+418
| +1% | +$1.83K |
|
3084
Instil Bio
TIL
$48.4M
| $164K | ﹤0.01% |
19,975
-41,050
| -67% | -$333K |
|
|
RDIB
3085
Reading International Class B
RDIB
$208M
| $162K | ﹤0.01% |
17,965
-2,723
| -13% | -$31.2K |
|
3086
NET Power
NPWR
$125M
| $161K | ﹤0.01% |
103,121
-84,545
| -45% | -$180K |
|
3087
Sypris Solutions
SYPR
$43.7M
| $160K | ﹤0.01% |
56,293
+13,975
| +33% | +$44.4K |
|
3088
Rigetti Computing
RGTI
$4.7B
| $160K | ﹤0.01% |
11,367
-160,405
| -93% | -$3.01M |
|
3089
QuickLogic
QUIK
$224M
| $158K | ﹤0.01% |
16,895
| – | – |
|
3090
Cohen & Co
COHN
$33.8M
| $155K | ﹤0.01% |
+10,265
| New | +$183K |
|
3091
Achieve Life Sciences
ACHV
$626M
| $154K | ﹤0.01% |
52,420
| – | – |
|
3092
Abeona Therapeutics
ABEO
$345M
| $154K | ﹤0.01% |
+34,371
| New | +$172K |
|
3093
Lipocine
LPCN
$17.1M
| $153K | ﹤0.01% |
19,122
+6,982
| +58% | +$60.8K |
|
3094
US Global Investors
GROW
$36.3M
| $146K | ﹤0.01% |
58,700
+5,056
| +9% | +$15.1K |
|
3095
Cineverse
CNVS
$55M
| $145K | ﹤0.01% |
60,720
-18,216
| -23% | -$43.9K |
|
3096
Savara
SVRA
$1.13B
| $144K | ﹤0.01% |
26,421
-143,708
| -84% | -$800K |
|
3097
Champions Oncology
CSBR
$85.1M
| $138K | ﹤0.01% |
23,973
-1,381
| -5% | -$8.77K |
|
|
ARTV
3098
Artiva Biotherapeutics
ARTV
$487M
| $131K | ﹤0.01% |
+20,370
| New | +$101K |
|
3099
NovaGold Resources
NG
$2.6B
| $130K | ﹤0.01% |
14,490
| – | – |
|
3100
Pliant Therapeutics
PLRX
$67.5M
| $125K | ﹤0.01% |
99,773
-21,983
| -18% | -$27.8K |
|
Similar funds
Dimensional Fund Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Dimensional Fund Advisors held 3,312 positions worth $481B, up 0.98% from $477B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Dimensional Fund Advisors's Q1 2026 filing shows 72 new, 1,935 increased, 1,135 reduced and 97 closed positions. Its largest new stake was Versant Media Group: 1,127,961 shares worth $41.7M. The largest sale was AstraZeneca, an estimated $609M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Financials and Industrials.
- Dimensional Fund Advisors's largest Q1 2026 buy was Versant Media Group: 1,127,961 shares worth $41.7M.
- Dimensional Fund Advisors added most to Amazon in Q1 2026, an estimated $1.61B increase.
- Dimensional Fund Advisors's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $331M.
- Dimensional Fund Advisors fully exited AstraZeneca in Q1 2026, selling an estimated $609M.
- Dimensional Fund Advisors's ten largest holdings make up 17% of its $481B portfolio in Q1 2026.
- Dimensional Fund Advisors opened 72 new positions and closed 97 in Q1 2026.
- Dimensional Fund Advisors's portfolio value rose 0.98% quarter-over-quarter to $481B.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.